NEW YORK, July 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
--
Questcor Pharmaceuticals, Inc. Analyst Notes
On July 3, 2014, Questcor Pharmaceuticals Inc.'s (Questcor) stock increased 2.76% to end the day at $95.00.The Company's stock rose 1.95% over the past five trading days compared to the Nasdaq Composite which rose 2.70% during the same trading period. The full analyst notes on Questcor are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/QCOR/report.pdf
--
Synta Pharmaceuticals Corp. Analyst Notes
On July 3, 2014, Synta Pharmaceuticals Corp. (Synta) stock increased 7.91% to end the day at $4.50 compared to the previous day's closing price of $4.17, making it one of the top gainers for the day. The Company's stock gained 10.02% over the past three trading days compared to the Nasdaq Composite which rose 1.76% during the same trading period. The full analyst notes on Synta are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/SNTA/report.pdf
--
Clovis Oncology, Inc. Analyst Notes
On June 23, 2014, Clovis Oncology, Inc. (Clovis) announced the successful first patient enrollment in its TIGER2 study. "We are pleased to begin enrolling TIGER2, our registration study for CO-1686 focused on T790M positive patients who have progressed following their first EGFR-targeted therapy," said Patrick J. Mahaffy, President and CEO of Clovis. "The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug. We remain committed to filing an NDA by mid-2015 based on this study and the ongoing TIGERX expansion cohorts." According to the Company, CO-1686 is the Company's novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. The full analyst notes on Clovis are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/CLVS/report.pdf
--
Alnylam Pharmaceuticals, Inc. Analyst Notes
On July 2, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it has elected Amy W. Schulman to the Company's Board of Directors. According to the Company, Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and she also served as the Business Unit Lead for Pfizer's Consumer Healthcare business. John Maraganore, Ph.D., CEO of Alnylam said, "Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board. Given our robust clinical progress and our potential transition to a commercial company in the coming years, Amy's addition to our Board comes at an opportune time as we advance RNAi therapeutics to patients." The full analyst notes on Alnylam are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/ALNY/report.pdf
--
Intrexon Corporation Analyst Notes
On July 1, 2014, Intrexon Corp. (Intrexon) announced that it has entered into a definitive agreement to acquire Trans Ova Genetics, L.C., (Trans Ova). Under the terms of agreement, Trans Ova will become a wholly owned subsidiary of Intrexon under the leadership of David Faber and his current management team. Further, Trans Ova stockholders will also receive approximately $60 million in upfront cash, $30 million in Intrexon common stock, and deferred payments of up to $20 million."Intrexon's mission is consistent with our own as we have sought to enable efficient, high-quality food production that supports the necessities of a growing global population in a sustainable way," said David Faber, D.V.M., President, Trans Ova. According to the Company, in FY 2013 Trans Ova generated revenues of $63.3 million and net income of $4.87 million. Intrexon expects the transaction to be completed in Q3 2014, subject to customary closing conditions. The full analyst notes on Intrexon are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/XON/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
